Beijing Minhai Biotechnology Co.

What Beijing Minhai Biotechnology Co. does

Beijing Minhai Biotechnology Co., Ltd. is a Beijing-based human vaccine developer, manufacturer, and commercializer, founded in 2004 and operating as a wholly-owned subsidiary of Shenzhen Kangtai Biological Products Co., Ltd. (Shenzhen Stock Exchange: 300601). The company focuses on inactivated, live attenuated, conjugate, and polysaccharide vaccines, with a current portfolio that includes a domestically exclusive cell-free Haemophilus influenzae type b combined (quadruple) vaccine, a measles-rubella combined live attenuated vaccine, the 23-valent pneumococcal polysaccharide vaccine (Weimin Feile, the only dual-dose 23-valent product in China), and a newly NMPA-approved Sabin strain-based inactivated polio vaccine (sIPV). It maintains a pipeline of 25 vaccines under study (5 awaiting production registration, 9 in clinical trials, 10 preclinical), supported by 100+ full-time R&D staff, 30 granted patents (including 29 invention patents and 1 foreign patent), and a 235-acre GMP-compliant facility in the Daxing Biomedical Industrial Base with combined annual production capacity exceeding 70 million doses across major lines.

Revenue is generated almost exclusively through one-time sale of vaccine doses to government and healthcare buyers, distributed via provincial vaccine bidding and procurement platforms across 21 Chinese provinces and cities. Sales operations are supported by academic promotion programs and KOL engagement targeting disease prevention and control centers, vaccination units, and healthcare institutions. International activity is nascent, with exports of measles vaccine concentrate to Pakistan beginning in 2018 and partnerships with WHO, NIH, DCVMN, Sanofi Pasteur, and INTRAVACC supporting technology transfer and potential global expansion. The company holds an Internet Drug Information Service Qualification Certificate and operates service hotlines for healthcare provider consultation, but specific pricing is not publicly disclosed.

Name

Beijing Minhai Biotechnology Co.

Legal name

Beijing Minhai Biological Technology Co., Ltd.

Website

https://en.biominhai.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Beijing Minhai Biotechnology Co. is a Beijing-based developer and manufacturer of human vaccines (inactivated, live attenuated, conjugate, and polysaccharide), wholly owned by Shenzhen Kangtai Biological Products, distributing through provincial government procurement platforms across 21 Chinese provinces with nascent international exports.

Ownership category

akta.pro rank

Product category

Human Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAAAEAA

Prophylactic Human Vaccines (routine, pediatric, adult)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

SECONDARYHLAIAEAB

Adult Vaccines

Healthcare & Life Sciences/Pharmaceuticals/Vaccines

SECONDARYHLAIAEAO

Vaccine Combination Products (Multivalent/Co-formulated)

Healthcare & Life Sciences/Pharmaceuticals/Vaccines

SECONDARYHLAIAEAM

Vaccine Clinical Development & Regulatory Affairs

Healthcare & Life Sciences/Pharmaceuticals/Vaccines

Keywords

• Human vaccine manufacturing
• Vaccine research development
• Biological products
• Immunization vaccines
• Polysaccharide conjugate vaccines

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Vaccine Product Sales: Production and sale of human vaccines including listed products covering the whole country with some products entering international markets. Products distributed through provincial vaccine bidding and procurement platforms.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Beijing Minhai Biotechnology Co. researches, develops, manufactures, and sells human vaccines using four core technology platforms: inactivated vaccines, live attenuated vaccines, conjugate vaccines, and polysaccharide vaccines. Its commercial portfolio includes vaccines for prevention of hepatitis B, Haemophilus influenzae type b, measles, rubella, pertussis, diphtheria, tetanus, pneumococcal disease, poliomyelitis, and varicella, distributed through provincial government procurement channels across China and selectively exported internationally.

Product overview

Beijing Minhai Biotechnology Co. is a vaccine company offering a portfolio of listed human vaccines covering prevention of pneumococcal diseases, Haemophilus influenzae type b, diphtheria, pertussis, tetanus, measles, rubella, and polio. The company develops, manufactures, and sells biological vaccine products including four listed vaccines: the Haemophilus influenzae type b conjugate vaccine (a domestic quadruple vaccine with proprietary IP), the Measles and Rubella Combined Live Attenuated Vaccine, the 23-valent pneumococcal polysaccharide vaccine (Weimin Feile, the only dual-dose formulation in China), and the Acellular Diphtheria-Pertussis-Tetanus and Haemophilus influenzae type b Combined Vaccine (the exclusive domestic quadruple vaccine). The portfolio also includes the newly approved Sabin strain-based inactivated polio vaccine (sIPV). The company has 25 vaccines under research with 5 awaiting production registration, 9 in clinical trials, and 10 in preclinical research.

Differentiator

Problem solved

Functional benefit

Brands

• Weimin Feile: Brand name for 23-valent pneumococcal polysaccharide vaccine

Products and services

• Haemophilus influenzae type b conjugate vaccine (Hib vaccine) A cell-free H. influenzae type b conjugate vaccine with completely independent intellectual property rights, used as a domestic quadruple vaccine component and undertaking 863 national scientific research projects. Targeted at pediatric immunization against Hib disease.
• Measles and Rubella Combined Live Attenuated Vaccine A combined live attenuated vaccine protecting against both measles and rubella viruses, used in pediatric and population immunization programs.
• 23-valent pneumococcal polysaccharide vaccine (Weimin Feile) The only dual-dose 23-valent pneumococcal polysaccharide vaccine in China, preventing pneumonia, meningitis, otitis media and bacteremia caused by 23 pneumococcal serotypes. Production capacity of 10 million doses per year, used for adult and high-risk population immunization.
• Acellular Diphtheria-Pertussis-Tetanus and Haemophilus influenzae type b Combined Vaccine (Quadruple vaccine) An exclusive domestic combined (quadruple) vaccine against diphtheria, pertussis, tetanus, and Haemophilus influenzae type b, designed to significantly improve infant vaccination compliance.
• Sabin strain-based inactivated polio vaccine (sIPV) A Sabin strain-based inactivated polio vaccine approved by China's NMPA, demonstrating superior safety (24% adverse reaction rate vs 33% for Sanofi Pasteur's wild-type IPV) and non-inferior immunogenicity across all three poliovirus serotypes with seroconversion rates exceeding 98% after primary immunization. Used in pediatric immunization against poliomyelitis.

Quantifiable outcome

• Seroconversion rates exceeding 98% after primary immunization and above 90% after booster immunization for sIPV vaccine
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered major and core.

• Pakistan National Institute of HealthmajorChannel Partner/ Reseller/ Distributor · 1 February 2018Exported 1 million doses of measles vaccine concentrate to Pakistan in February 2018, becoming the first enterprise to export measles vaccine concentrate to Pakistan. Subsequent additional export of 1 million doses.
• World Health Organization (WHO)coreStrategic or Co-development PartnerEstablished strategic partnership with WHO for exploring new areas of high-end vaccine development. Collaboration on international vaccine standards and development.
• National Institutes of Health (NIH)coreStrategic or Co-development PartnerWorking with NIH for vaccine research and development collaboration. Strategic partnership for high-end vaccine technology development.
• Developing Countries Vaccine Alliance (DCVMN)coreStrategic or Co-development PartnerStrategic cooperation with DCVMN for exploring new areas of high-end vaccine development and supporting vaccine access in developing countries.
• Sanofi Pasteur (France)majorTechnology or IntegrationExclusive introduction of human diploid cell rabies vaccine gold standard technology from Sanofi Pasteur, France. Long-standing technology partnership for vaccine development.
• INTRAVACC (Netherlands)majorTechnology or IntegrationPartnership with Dutch INTRAVACC for inactivated polio vaccine technology. Technology transfer and development collaboration.

Scale indicators17 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Walvax Biotechnology Co., Ltd. Major Chinese vaccine manufacturer offering HepB, Hib, and other pediatric vaccines competing head-to-head against Minhai in China's Expanded Program on Immunization and tender-based procurement.
• Beijing Zhifei Biological Products Co., Ltd. Chinese vaccine company with strong HPV and pediatric vaccine presence, overlapping in distribution channels and target disease categories.
• Sinovac Biotech Ltd. Beijing-based vaccine developer and manufacturer producing inactivated and combination vaccines for both domestic Chinese and international markets, with overlapping product and channel positioning.
• Hualan Biological Engineering Inc. Chinese manufacturer of vaccines and blood products, including influenza and pediatric vaccines, competing in overlapping segments through similar government procurement channels.
• CanSino Biologics Inc. Chinese vaccine developer with established pipeline in meningitis, polio and combination vaccines; competes in Chinese immunization tenders with comparable technology platforms.

Broad incumbents

• Sinopharm / China National Biotec Group (CNBG): China's state-controlled largest vaccine manufacturer with the broadest domestic portfolio and global reach; dominant incumbent competing with Minhai across multiple disease segments.
• Sanofi Pasteur: Global vaccine leader referenced by Minhai as the wild-type IPV comparator; an existing technology partner on rabies and a benchmark competitor across polio and combination categories.
• GSK Vaccines: Global vaccines incumbent with broad pediatric and adult portfolio; competes in the same priority pathogen categories (Hib, pneumococcal, polio) in markets Minhai targets.

Emerging players

• Serum Institute of India: World's largest vaccine manufacturer by dose volume, supplying WHO prequalified pediatric and combination vaccines to similar emerging-market buyers that Minhai and its DCVMN partners target.
• Bharat Biotech: Indian vaccine developer producing combination and pediatric vaccines with WHO PQ; comparable emerging-market vaccine competitor with similar pricing-tier positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/beijing-minhai-biotechnology-co-ltd-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beijing Minhai Biotechnology Co.